Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

The focus of this research is on increasing the uptake of the human papillomavirus (HPV) vaccine in young cancer survivors, a vulnerable population at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent HPV infection. An effective vaccine exists that can prevent these cancers, but HPV vaccine uptake is low among young cancer survivors. This research will evaluate the effectiveness and implementation of an evidence-based intervention, adapted for use by healthcare providers in pediatric oncology clinics, to increase the uptake of HPV vaccine among young cancer survivors 9-17 years of age. Results of this research will provide important information that can be used to implement new strategies to increase the uptake of the HPV vaccine among young cancer survivors.

NCT Number	NCT04469569
Lead Sponsor	University of Alabama at Birmingham Collaborators: National Cancer Institute (NCI)
Conditions	Papillomavirus Vaccines
Enrollment	8,120 participants
Start Date	2021-02-01
Primary Completion	2025-01-26 (estimated)
Study Completion	2025-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-03